The first barrier Grivas notes is limited infusion room capacity and the need for rapid chair turnover. Other external barriers for patients include transportation and lodging. Grivas highlights that ...
Clinical Trials Arena on MSN22h
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancerThe company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback